Category
blog
-
2023
-
FDA Approves Sandoz’ High-Concentration Version of Adalimumab Biosimilar, Hyrimoz
-
FDA Approves Sandoz’s Citrate-Free Adalimubab Formulation
-
AbbVie Hits Snag for Parkinson’s Disease Candidate
-
AstraZeneca and Ionis build case for amyloidosis drug eplontersen
-
FDA Approves First-Ever Treatment for Activated Phosphoinositide 3-Kinase Delta Syndrome
-
NICE Recommends Upstaza for Rare Genetic Disorder
-
Incyte Gets CRL for Jakafi Extended-Release Tablets
-
Glenmark Pharmaceuticals’ Generic of Leo Pharma’s Enstilar Approved
-
Cyclerion’s Mitochondrial Diseases Candidate Gets Orphan Drug Nod
-
AstraZeneca, Amgen’s asthma launch Tezspire picks up backing from England’s NICE